Indian Journal of Animal Research

Indian Journal of Animal Research cover
Volume 60 · Issue 6 · 2026/06/12

Protective Effects of Suberoylanilide Hydroxamic Acid and Dapagliflozin Administration on the Liver of Type 2 Diabetic Rats

Zaenah Zuhair Alamri
Sahar J. Melebary
174 Views

Submitted

2025/07/03

First Online

2026/06/12

doi

10.18805/IJAR.BF-2040

Cite article - Zaenah Zuhair Alamri, Sahar J. Melebary. (2026). Protective Effects of Suberoylanilide Hydroxamic Acid and Dapagliflozin Administration on the Liver of Type 2 Diabetic Rats. Indian Journal of Animal Research. 60(6): 1009–1020. doi: 10.18805/IJAR.BF-2040

Abstract

Background: Type 2 diabetes mellitus (T2DM) patients have hepatic disorders risk. This study investigated liver-protective effects of suberoylanilide hydroxamic acid (SAHA) and dapagliflozin (DAPA) in T2DM rats.

Methods: T2DM induced by high fat diet (HFD) and single Streptozotocin (STZ) injection (35 mg/kg i.p.). Forty rats sorted into 4 groups: NC (negative control), T2DM, T2DM+SAHA (5 mg/kg/i.p. for 8 weeks) and T2DM+DAPA (1mg/kg/p.o. for 8 weeks). At experimental end, levels of fasting blood glucose (FBG), fasting insulin, hepatic function tests [gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, total protein], lipid profiles [total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglyceride (TG)] measured in serum. Hepatic tissue homogenization prepared for estimating oxidative stress biomarkers [glutathione (GSH), malonaldehyde (MDA), superoxide dismutase (SOD)]. Hepatic histopathological examination made under light microscope.

Result: After 8 weeks treatment, diabetic rats showed elevated FBG, insulin, liver enzymes (GGT, ALT, AST), bilirubin, TG, TC, LDL-C, MDA, with reductions in albumin, proteins, HDL-C, GSH, SOD. Histopathological liver damage observed. SAHA and DAPA improved metabolic, oxidative stress and liver function. DAPA was effective in improving FBG and lipid profiles, while SAHA showed effective on insulin resistance and antioxidant. Histological liver improvements were more pronounced in SAHA group. SAHA and DAPA offer hepatoprotection in T2DM by improving oxidative stress, lipid metabolism and insulin sensitivity and preserving liver structure.

References

  1. Ahmed, S.W.M., Soliman, A., Ahmed Amer, A.E., El Shahat, R.M., Amin, M.M., Taha, R.S., Awad, M.M.Y., Abdel, H.A.M., El- Sayed, M.S. et al . (2023). Effect of dapagliflozin against NAFLD and dyslipidemia in type 2 diabetic albino rats: Possible underlying mechanisms. Eur. Rev. Med. Pharmacol. Sci. 27(17): 8101-8109. Abbas, A., Ramadan, W., Abdel Kawy, H. and Alhaddad, A. (2019). Hepatoprotective Effects of suberoylanilide hydroxamic acid (A histone deacetylase inhibitor) in immunological liver injury in rats. Journal of Pharmaceutical Research International . 30(3): 1-15. Abdulwahab, D.A., El-Missiry, M.A., Shabana, S., Othman, A.I. and Amer, M.E. (2021). Melatonin protects the heart and pancreas by improving glucose homeostasis, oxidative stress, inflammation and apoptosis in T2DM-induced rats. Heliyon . 7(3): e06474. Al-Ani, I., Al-Mishadani, N., Muslih, R.K. and Hamoodi, S.R. (2009). Histological liver changes in streptozotocin induced diabetic mice. Med. J. Malaysia . 8(1): 1-4. Arab, H.H., Fikry, E.M., Alsufyani, S.E., Ashour, A.M., El-Sheikh, A.A.K., Darwish, H.W., Al-Hossaini, A.M., Saad, M.A., Al-Shorbagy, M.Y. and Eid, A.H. (2023). Stimulation of autophagy by dapagliflozin mitigates cadmium-induced testicular dysfunction in rats: The role of AMPK/mTOR and SIRT1/Nrf2/HO-1 pathways. Pharmaceuticals ( Basel ). 16(7): 1006. Bae, C.S., Lee, Y. and Ahn, T. (2023). Therapeutic treatments for diabetes mellitus-induced liver injury by regulating oxidative stress and inflammation. Appl. Microsc . 53(1): 4. Bakhdar, F.A., Abdel, K.H.S., Magadmi, R.M., El-Kordy, E.A. and Alamri, A.S. (2023). Effect of histone deacetylase inhibitor (Vorinostat) on new-onset diabetes induced by tacrolimus. J. Taibah Univ Med Sci . 18(1): 9-18. Bica, I.C., Stoica, R.A., Salmen, T., Janez, A., Volcansek, S., Popovic, D., Muzurovic, E., Rizzo, M. and Stoian, A.P. (2023). The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: A systematic review of randomized controlled trials. Medicina (Kaunas ). 59(6): 1136. Bocchi, L., Motta, B.M., Savi, M., Vilella, R., Meraviglia, V., Rizzi, F., Galati, S., Buschini, A., Lazzaretti, M., Pramstaller, P. P., Rossini, A. and Stilli, D. (2019). The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restores cardiomyocyte contractility in a rat model of early diabetes. Int. J. Mol. Sci . 20(8): 1873. Cabrera, S.M., Colvin, S.C., Tersey, S.A., Maier, B., Nadler, J.L. and Mirmira, R.G. (2013). Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. Clin. Exp. Immunol . 172(3): 375-382. Chen, Y., Du, J., Zhao, Y. T., Zhang, L., Lv, G., Zhuang, S., Qin, G. and Zhao, T.C. (2015). Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc Diabetol. 14: 99. Colussi, C., Berni, R., Rosati, J., Straino, S., Vitale, S., Spallotta, F., Baruffi, S., Bocchi, L., Delucchi, F., Rossi, S., Savi, M., Rotili, D. et al . (2010). The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovasc Res . 87(1): 73-82. Dewanjee, S., Vallamkondu, J., Kalra, R. S., Chakraborty, P., Gangopadhyay, M., Sahu, R., Medala, V., John, A., Reddy, P.H., De Feo, V. and Kandimalla, R. (2021). The emerging role of HDACs: Pathology and therapeutic targets in diabetes mellitus. Cells . 10(6): 1340. Elsharkawi, I., Parambath, D., Saber-Ayad, M., Khan, A.A. and El- Serafi, A.T. (2020). Exploring the effect of epigenetic modifiers on developing insulin-secreting cells. Hum Cell. 33(1): 1-9. Eriksson, J.W., Lundkvist, P., Jansson, P. A., Johansson, L., Kvarnstrom, M., Moris, L., Miliotis, T., Forsberg, G.B., Riserus, U., Lind, L. and Oscarsson, J. (2018). Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study. Diabetologia . 61(9): 1923-1934. Esterline, R.L., Vaag, A., Oscarsson, J. and Vora, J. (2018). Mechanisms in endocrinology: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism? Eur. J. Endocrinol . 178(4): R113-R125. Grant, S., Easley, C. and Kirkpatrick, P. (2007). Vorinostat. Nat Rev Drug Discov. 6(1): 21-22. Hadden, M.J. and Advani, A. (2018). Histone deacetylase inhibitors and diabetic kidney disease. Int. J. Mol. Sci . 19(9): 2630. Harris, K. and Nealy, K.L. (2020). Cardiorenal outcomes in type 2 diabetes. Consensus Statement. 43: S98-S110. Hazem, R.M., Ibrahim, A.Z., Ali, D.A. and Moustafa, Y.M. (2022). Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int. Immunopharmacol . 104: 108503. Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M. and Shimada, A. (2017). Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open- label, active-controlled trial. Diabetes Care . 40(10): 1364-1372. Joannides, C.N., Mangiafico, S.P., Waters, M.F., Lamont, B.J. and Andrikopoulos, S. (2017). Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity. Diabetes Obes Metab. 19(8): 1135-1146. Kashiwagi, A. (2001). Complications of diabetes mellitus and oxidative stress. Japan Medical Association Journal . 44(12): 521-528. Kelly, W.K., O’Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P. et al . (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17): 3923-3931. Khajuria, P., Raghuwanshi, P., Rastogi, A., Koul, A., Zargar, R. and Kour, S. (2018). Hepatoprotective effect of seabuckthorn leaf extract in streptozotocin induced diabetes mellitus in wistar rats. Indian Journal of Animal Research . 52(12): 1745-1750. doi: 10.18805/ijar.B-3439 . Khan, N., Kakar, A., Rabbani, I. and Naseem, M. (2025). Quercetin verses metformin, comparative efficacy on the lipid metabolism gene expression in different organs of diabetic wistar rats. Indian Journal of Animal Research . 60(3): 439-446. doi: 10.18805/IJAR.BF-1968 . Leng, W., Wu, M., Pan, H., Lei, X., Chen, L., Wu, Q., Ouyang, X. and Liang, Z. (2019). The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann. Transl. Med . 7(18): 429. Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Dona, G., Fossati, G., Sozzani, S., Azam, T., Bufler, P., Fantuzzi, G. et al . (2002). The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. USA. 99(5): 2995-3000. Lundh, M., Christensen, D.P., Damgaard Nielsen, M., Richardson, S.J., Dahllof, M.S., Skovgaard, T., Berthelsen, J., Dinarello, C.A., Stevenazzi, A., Mascagni, P., Grunnet, L.G., Morgan, N.G. and Mandrup-Poulsen, T. (2012). Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia . 55(9): 2421- 2431. Millar, P.J., Pathak, V., Moffett, R.C., Pathak, N.M., Bjourson, A.J., O’Kane, M.J., Flatt, P.R. and Gault, V.A. (2016). Beneficial metabolic actions of a stable GIP agonist following pre- treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol. Cell. Endocrinol. 420: 37-45. Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., Leerapun, A., Phrommintikul, A., Buranapin, S., Chattipakorn, N. and Thongsawat, S. (2021). The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J. Gastroenterol Hepatol . 36(10): 2952-2959. Rao, K.V., Rani, M.U., Reddy, A.G., Kumar, B.A., Sree, K., Rajender, B. and Hanuman, D. (2023). Bovine lactoferrin mitigates oxidative stress and inflammation in CCL 4 and high-fat diet-induced NAFLD in C57BL/6 mice. Indian Journal of Animal Research . 1-9. doi: 10.18805/IJAR.B-5327 . Rodriguez, V., Plavnik, L. and Tolosa de Talamoni, N. (2018). Naringin attenuates liver damage in streptozotocin-induced diabetic rats. Biomed Pharmacother . 105: 95-102. Salem, I.S., El Mageed, N.M.A. and El Rahman, H. (2022). Effect of green coffee bean extract on rats suffering from diabetes. Journal of Pharmaceutical Negative Results . 13(9): 8130-8143. Silva, G., Ferraresi, C., de Almeida, R.T., Motta, M.L., Paixao, T., Ottone, V. O., Fonseca, I.A., Oliveira, M.X., Rocha-Vieira, E., Dias-Peixoto, M.F., Esteves, E.A., Coimbra, C.C., Amorim, F.T. and Magalhaes, F.C. (2020). Insulin resistance is improved in high-fat fed mice by photobiomodulation therapy at 630 nm. J. Biophotonics . 13(3): e201960140. Szekeres, Z., Toth, K. and Szabados, E. (2021). The effects of SGLT2 inhibitors on lipid metabolism. Metabolites . 11(2): 87. Tanbek, K., Ozerol, E., Yilmaz, U., Yilmaz, N., Gul, M. and Colak, C. (2022). Alpha lipoic acid decreases neuronal damage on brain tissue of STZ-induced diabetic rats. Physiol Behav . 248: 113727. Tang, L., Wu, Y., Tian, M., Sjostrom, C.D., Johansson, U., Peng, X.R., Smith, D.M. and Huang, Y. (2017). Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab . 313(5): E563-E576. Teo, Z.L., Tham, Y.C., Yu, M., Chee, M.L., Rim, T.H., Cheung, N., Bikbov, M.M., Wang, Y.X., Tang, Y., Lu, Y. et al . (2021). Global Prevalence of diabetic retinopathy and projection of burden through 2045: Systematic Review and meta- analysis. Ophthalmology . 128(11): 1580-1591. Ulger, T.G. and Cakiroglu, F.P. (2020). The effects of onion ( Allium cepa L.) dried by different heat treatments on plasma lipid profile and fasting blood glucose level in diabetic rats. Avicenna J. Phytomed . 10(4): 325-333. Wang, L., Bai, Y., Cao, Z., Guo, Z., Lian, Y., Liu, P., Zeng, Y., Lyu, W. and Chen, Q. (2024). Histone deacetylases and inhibitors in diabetes mellitus and its complications. Biomed Pharmacother . 177: 117010. Wang, Y., Zhao, L., Jiao, F.Z., Zhang, W.B., Chen, Q. and Gong, Z.J. (2018). Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-beta1 signal pathway. Hepatobiliary Pancreat Dis. Int . 17(5): 423-429. Wu, Q., Cheng, Z., Zhu, J., Xu, W., Peng, X., Chen, C., Li, W., Wang, F., Cao, L., Yi, X., Wu, Z., Li, J. and Fan, P. (2015). Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line. Sci. Rep . 5(1): 9520. Xu, B., Li, S., Kang, B. and Zhou, J. (2022). The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 21(1): 83. Ying, X., Chen, X., Wang, T., Zheng, W., Chen, L. and Xu, Y. (2020). Possible osteoprotective effects of myricetin in STZ induced diabetic osteoporosis in rats. Eur. J. Pharmacol . 866: 172805. Zhang, Y., Geng, Z., Xu, P. and Gao, X. (2013). Effect of suberoylanilide hydroxamic acid on liver injury induced by lethal hemorrhagic shock in rats first entering high altitude. Chinese Journal of Anesthesiology . pp 477-480. Zhao, Y., Zhou, P., Liu, B., Bambakidis, T., Mazitschek, R., Alam, H.B. and Li, Y. (2015). Protective effect of suberoylanilide hydroxamic acid against lipopolysaccharide-induced liver damage in rodents. J. Surg. Res . 194(2): 544-550. Zhu, Y., Su, Y., Zhang, J., Zhang, Y., Li, Y., Han, Y., Dong, X., Li, W. and Li, W. (2021). Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR mediated autophagy. Mol. Med. Rep. 23(6): 1-15.
EDITORIAL BOARD

Guided by Experienced Academic Leadership

Distinguished scholars and subject experts committed to editorial excellence, scientific integrity and rigorous peer review.

View Full Board
Yashpal Singh Malik
Chief Editor

Yashpal Singh Malik

Deputy Director General (Agricultural Education)Indian Council of Agricultural Research, Headquarters, New Delhi , India

L.D. Singla
Associate chief editor

L.D. Singla

Professor and HeadAbhilashi University, Chachyot, Himachal Pradesh, India

Vilas G. Atkare
Editor

Vilas G. Atkare

DeanDr. Panjabrao Deshmukh Krishi Vidyapeeth, Akola, Krishi Nagar, Maharashtra, India

S. Maya
Editor

S. Maya

Associate Dean and Professor & HeadKerala Veterinary and Animal Sciences University, Mannuthy, Thrissur, Kerala, India